Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Prothena Corp (PRTA) and AzurRx BioPharma Inc (AZRX).
Prothena Corp (PRTA)
Oppenheimer analyst Jay Olson maintained a Hold rating on Prothena Corp today. The company’s shares opened today at $13.64, close to its 52-week low of $8.63.
According to TipRanks.com, Olson is a 1-star analyst with an average return of -2.3% and a 45.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Prothena Corp with a $20 average price target.
See today’s analyst top recommended stocks >>
AzurRx BioPharma Inc (AZRX)
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on AzurRx BioPharma Inc. The company’s shares opened today at $2.30.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 1.0% and a 54.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Anchiano Therapeutics Ltd, Avenue Therapeutics Inc, and Evofem Biosciences Inc.
AzurRx BioPharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.50, which is a 182.6% upside from current levels. In a report issued on March 18, Maxim Group also maintained a Buy rating on the stock with a $5 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
